Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28126 | 213 | 25.6 | 49% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
382 | 3 | DUPUYTRENS DISEASE//PRESSURE ULCER//VARICOSE VEINS | 31698 |
1697 | 2 | VARICOSE VEINS//PHLEBOLOGY//CHRONIC VENOUS INSUFFICIENCY | 6748 |
28126 | 1 | CALCIUM DOBESILATE//DOBESILATE//BONE MINERAL DENS MEASUREMENT | 213 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | CALCIUM DOBESILATE | authKW | 4739771 | 22% | 72% | 46 |
2 | DOBESILATE | authKW | 1023985 | 5% | 71% | 10 |
3 | BONE MINERAL DENS MEASUREMENT | address | 286717 | 1% | 100% | 2 |
4 | VEGF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR | authKW | 286717 | 1% | 100% | 2 |
5 | SERV HISTOL | address | 168392 | 5% | 11% | 11 |
6 | 1 NAPHTHALENEMONOSULFONATE | authKW | 143359 | 0% | 100% | 1 |
7 | 2 5 DIHYDROXYPHENYLSULFONATE 2 5DHPS | authKW | 143359 | 0% | 100% | 1 |
8 | 25 DIHYDROXYPHENYLSULFONATE | authKW | 143359 | 0% | 100% | 1 |
9 | CARBON IRON NANOPARTICLES | authKW | 143359 | 0% | 100% | 1 |
10 | CARDIAC LYMPHATIC OBSTRUCTION | authKW | 143359 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Peripheral Vascular Diseases | 592 | 16% | 0% | 34 |
2 | Pharmacology & Pharmacy | 284 | 23% | 0% | 49 |
3 | Medicine, Research & Experimental | 107 | 9% | 0% | 20 |
4 | Medicine, General & Internal | 78 | 10% | 0% | 22 |
5 | Ophthalmology | 74 | 6% | 0% | 12 |
6 | Physiology | 67 | 7% | 0% | 15 |
7 | Cardiac & Cardiovascular System | 63 | 8% | 0% | 17 |
8 | Chemistry, Medicinal | 38 | 5% | 0% | 10 |
9 | Chemistry, Analytical | 11 | 5% | 0% | 10 |
10 | Surgery | 8 | 6% | 0% | 12 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BONE MINERAL DENS MEASUREMENT | 286717 | 1% | 100% | 2 |
2 | SERV HISTOL | 168392 | 5% | 11% | 11 |
3 | DIABET METAB EACH UNIT | 143359 | 0% | 100% | 1 |
4 | DIABET RETINOPATHY RETINAL VASC DIS | 143359 | 0% | 100% | 1 |
5 | EUROPEAN VIS CLIN NETWORK EVICR NETOPHT | 143359 | 0% | 100% | 1 |
6 | GLOBAL MED AFFAIRS INFECT DIS OTX | 143359 | 0% | 100% | 1 |
7 | SERV ANAT PATOL HOSP | 143359 | 0% | 100% | 1 |
8 | SERV FARMACOL CLINFUNDACIO CATALA FARMACOL | 143359 | 0% | 100% | 1 |
9 | VICTOR SMORGON DIABET | 143359 | 0% | 100% | 1 |
10 | ARZNEIMITTELFOR | 71678 | 0% | 50% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ACTA THERAPEUTICA | 9241 | 2% | 2% | 4 |
2 | LYMPHOLOGY | 8575 | 4% | 1% | 8 |
3 | ANGIOLOGY | 5287 | 6% | 0% | 13 |
4 | GIORNALE DI GERONTOLOGIA | 5118 | 0% | 4% | 1 |
5 | ACTA MORPHOLOGICA HUNGARICA | 4511 | 1% | 2% | 2 |
6 | ZEITSCHRIFT FUR LYMPHOLOGIE-JOURNAL OF LYMPHOLOGY | 3332 | 0% | 2% | 1 |
7 | NEUROLOGICAL RESEARCH | 2773 | 4% | 0% | 8 |
8 | VASA-JOURNAL OF VASCULAR DISEASES | 1876 | 2% | 0% | 5 |
9 | PHLEBOLOGY | 1855 | 2% | 0% | 4 |
10 | EUROPEAN JOURNAL OF MEDICAL RESEARCH | 1802 | 2% | 0% | 4 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | ALLAIN, H , RAMELET, AA , POLARD, E , BENTUE-FERRER, D , (2004) SAFETY OF CALCIUM DOBESILATE IN CHRONIC VENOUS DISEASE, DIABETIC RETINOPATHY AND HAEMORRHOIDS.DRUG SAFETY. VOL. 27. ISSUE 9. P. 649-660 | 30 | 57% | 21 |
2 | ISKESEN, I , SARIBULBUL, O , CERRAHOGLU, M , ONUR, E , TEKIN, C , SIRIN, H , (2006) CARDIOPROTECTIVE EFFECT OF CALCIUM DOBESILATE DURING OPEN-HEART SURGERY.ACTA CARDIOLOGICA. VOL. 61. ISSUE 1. P. 69-74 | 15 | 94% | 1 |
3 | RABE, E , BALLARINI, S , LEHR, L , (2016) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL STUDY ON THE EFFICACY AND SAFETY OF CALCIUM DOBESILATE IN THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY.PHLEBOLOGY. VOL. 31. ISSUE 4. P. 264 -274 | 17 | 59% | 0 |
4 | ARCEO, A , BERBER, A , TREVINO, C , (2002) CLINICAL EVALUATION OF THE EFFICACY AND SAFETY OF CALCIUM DOBESILATE IN PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY OF THE LOWER LIMBS.ANGIOLOGY. VOL. 53. ISSUE 5. P. 539-544 | 21 | 66% | 6 |
5 | ANGEHRN, F , (1995) EFFICACY AND SAFETY OF CALCIUM DOBESILATE IN PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY - AN OPEN-LABEL, MULTICENTER STUDY.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL. VOL. 56. ISSUE 4. P. 346-357 | 13 | 100% | 6 |
6 | FLOTA-CERVERA, F , FLOTA-RUIZ, C , TREVINO, C , BERBER, A , (2008) RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE LYMPHAGOGUE EFFECT AND CLINICAL EFFICACY OF CALCIUM DOBESILATE IN CHRONIC VENOUS DISEASE.ANGIOLOGY. VOL. 59. ISSUE 3. P. 352-356 | 11 | 73% | 9 |
7 | ZHANG, XQ , (2013) THERAPEUTIC EFFECTS OF CALCIUM DOBESILATE ON DIABETIC NEPHROPATHY MEDIATED THROUGH REDUCTION OF EXPRESSION OF PAI-1.EXPERIMENTAL AND THERAPEUTIC MEDICINE. VOL. 5. ISSUE 1. P. 295-299 | 10 | 71% | 1 |
8 | HARITOGLOU, C , GERSS, J , SAUERLAND, C , KAMPIK, A , ULBIG, MW , (2009) EFFECT OF CALCIUM DOBESILATE ON OCCURRENCE OF DIABETIC MACULAR OEDEMA (CALDIRET STUDY): RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE TRIAL.LANCET. VOL. 373. ISSUE 9672. P. 1364 -1371 | 14 | 54% | 16 |
9 | IBANEZ, L , BALLARIN, E , VIDAL, X , LAPORTE, JR , (2000) AGRANULOCYTOSIS ASSOCIATED WITH CALCIUM DOBESILATE - CLINICAL COURSE AND RISK ESTIMATION WITH THE CASE-CONTROL AND THE CASE-POPULATION APPROACHES.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 56. ISSUE 9-10. P. 763-767 | 13 | 72% | 23 |
10 | AKGUN, OO , ARSLAN, C , SUZER, O , BOZKURT, AK , (2011) THE EFFECTS OF CALCIUM DOBESILATE AND MICRONIZED PURIFIED FLAVONOID FRACTIONS ON MYOCARDIAL PROTECTION.TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. VOL. 19. ISSUE 3. P. 417-424 | 13 | 52% | 0 |
Classes with closest relation at Level 1 |